NVA237 is being developed and commercialised by Novartis both as a monotherapy and in combination with their once daily bronchodilator indacaterol (QAB149), under the terms of the agreement signed in April 2005.The study is a randomised, double-blind, multi-centre, placebo-controlled trial designed to evaluate the efficacy, safety and dose response of NVA237 in patients diagnosed with COPD over a four week period.Within this team you will be given opportunities and encouragement to develop further skills and experience and drive your career forward when matched with your hard work and effort.G&T is an independent construction and property consultancy working across all sectors of the built environment.The Company has development collaborations with a number of companies, including GSK, Chiesi and Arakis.We are seeking a Category/Package Manager for a project based in Hatfield to assist in procurement and contract administration within the utilities sector.Mr Shinichi Tamura, President & CEO of Sosei, said: "COPD is increasingly being recognised as a common and costly disease with high patient unmet need.The commencement of the Phase IIb trial represents a further important step in validating the clinical profile of NVA237, which we believe to be a very promising product with the potential to improve upon existing therapies".
In addition, there is a preclinical pipeline of other opportunities, two exploratory developments and a number of research projects.
About Vectura Vectura's (LSE: VEC) principal focus is to combine its proprietary pulmonary formulation and device technologies with existing, off-patent drugs to develop inhaled drugs for the treatment of both lung diseases and conditions where delivery via the lungs can provide significant benefits, such as a rapid onset of action, improved efficacy and improved tolerability compared with current therapies.
The Company will seek to license its lead products to pharmaceutical companies with established sales and marketing infrastructures for the later stages of development and for commercialisation, typically prior to Phase III clinical development.
We focus on minimising risk and creating opportunities to maximise the value of our clients’ developments and property assets.
We deliver Project Leadership, Cost Certainty, Construction Success and Specialist Consultancy working across all sectors of the built environment.